



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 35175

Title: Neoadjuvant therapy for resectable pancreatic cancer

Reviewer’s code: 01430761

Reviewer’s country: Japan

Science editor: Fang-Fang Ji

Date sent for review: 2017-06-27

Date reviewed: 2017-06-27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a well-written review of neoadjuvant chemotherapy for resectable pancreatic cancer. 1. In the first paragraph of Introduction, the authors mentioned about “recurrent disease within five years” in resected pancreatic cancer. However, as the authors did comment later, earlier recurrent diseases are of clinical importance. Please also add comments on the role of diagnostic laparoscopy to evaluate occult metastatic diseases prior to neoadjuvant chemotherapy. 2. Please add the definition of resectable, borderline resectable and locally advanced disease as a table in “Resectability.” 3. Please add some comments on pathological response in addition to radiological response. 4. In Table 1, the authors described as negative/positive resection margins. However, as the authors discussed in the text, surgically negative margin is theoretically confirmed by preoperative images. It would be easier to understand if the authors can put corresponding comments of neoadjuvant vs. adjuvant therapy in the same line such as chemotherapy rate, biliary decompression, the likelihood of early recurrence and so on.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

5. Comments in the last column of Table 1 are somewhat unclear (Intact vascular supply...).



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 35175

Title: Neoadjuvant therapy for resectable pancreatic cancer

Reviewer’s code: 03408355

Reviewer’s country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2017-06-27

Date reviewed: 2017-06-29

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This paper overviewed the recent progress on the neoadjuvant therapy for resectable pancreatic cancer. However, the neoadjuvant therapy for treating unresectable pancreatic cancer may be an more important clinical question, which should be further elaborated. The following were some questions to be addressed: 1. Is there any RCTs on the efficacy of neoadjuvant therapy in treating such disease? A meta analysis is suggested, if possible. 2. The text should be reorganized to be more reasonable. 3. More recent publications should be cited in the paper, especially those in recent 5 years. 4. A diagram illustrating the selection of neoadjuvant therapy for resectable pancreatic cancer could be added, which may help the readers understand better. 5. Several language mistakes were found in the paper. Please check the whole text and correct all the mistakes.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 35175

Title: Neoadjuvant therapy for resectable pancreatic cancer

Reviewer’s code: 02445717

Reviewer’s country: Spain

Science editor: Fang-Fang Ji

Date sent for review: 2017-06-27

Date reviewed: 2017-07-09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

It is a good review paper about the role of the neoadjuvant therapy for resectable pancreatic cancer (PC). Based in the bad prognostic and the poor outcomes observed with old treatment modalities in PC. They carry out a comprehensive review of the current literature for provide an overview of the most recent evidence on this topic, appraise the potential benefits and disadvantages of neoadjuvant versus surgery first approach. They conclude that there is still insufficient evidence to fully support the use of neoadjuvant therapy for all patients with radiologically resectable PC. Emphasis is placed on the need to carry out randomized controlled trials to address many of the questions that are still unanswered. Meanwhile, since each patient is unique, proposing neoadjuvant therapy with one-size-fits-all approach should be discouraged and patients should become active participants and share with their physicians the responsibility of selecting the treatment strategy that fits best with their goals and values.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 35175

Title: Neoadjuvant therapy for resectable pancreatic cancer

Reviewer's code: 02570566

Reviewer's country: South Korea

Science editor: Fang-Fang Ji

Date sent for review: 2017-06-27

Date reviewed: 2017-07-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

To the authors, The title of this manuscript is that neoadjuvant therapy for resectable pancreatic cancer. In this study, the authors have described to provide the readers an overview of the most recent evidence on the use of neoadjuvant therapy for resectable pancreatic cancer. The manuscript is well design and written. This review article is adjustable for support their hypothesis. The manuscript should be published if they correct some minor comments as described in bellow. Manor comments Some data (references) need to be made with table or figures, it should be summarized.